Deltex appoints new Group Finance Director

RNS Number : 8929Q

Deltex Medical Group PLC

23 June 2015

 

23 June 2015

Deltex Medical Group plc

("Deltex Medical" or "the Company")

Deltex appoints new Group Finance Director

Deltex Medical Group plc, the global leader in oesophageal Doppler monitoring ("ODM"), today announces that it has appointed Jonathan Shaw to join the Board as Group Finance Director with effect from 1 September 2015.

Jonathan David Shaw, aged 46, is a Chartered Certified Accountant (FCCA).

Mr Shaw has spent the majority of his career working at either director or senior manager level in professional accounting and auditing firms most recently with Grant Thornton UK LLP in London and including PricewaterhouseCoopers LLP in Southampton where he was Deltex Medical's senior audit manager for nearly four years. During his career Mr Shaw has undertaken a number of secondments to industry or government and spent almost three years at the Financial Reporting Council, the UK's independent regulator responsible for promoting high quality corporate governance and reporting to foster investment, as a case officer at the Financial Reporting Review Panel. Mr Shaw is a member of the Association of Chartered Certified Accountant's Global Corporate Reporting Forum and a specialist business mentor for The Prince's Trust.

Nigel Keen, Deltex Medical's Chairman, commented:

"We are delighted that Jonathan Shaw will join the Deltex Board as Group Finance Director. Jonathan knows our business well and has a wealth of management and financial reporting experience that will help us develop our business as we grow internationally."

The following information regarding Mr Shaw's appointment is required to be disclosed under Schedule Two paragraph (g) of the AIM Rules for Companies:

Jonathan Shaw does not currently hold shares in the Company. Details of other directorships/partnerships held are listed below:

Current	Previous
JDS Accountants Limited	Ariel Solar 08 Limited

Save as disclosed above, there are no other details to be disclosed regarding Mr. Shaw's' appointment as required under paragraph (g) of Schedule 2 of the AIM Rules.

For further information, please contact:-

Deltex Medical Group plc	01243 774 837 [e-mail]
Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Barry Curtis, Company Secretary
Nominated Adviser & Broker
Arden Partners plc	020 7614 5900
Chris Hardie
Joint Broker Zeus Capital Limited Phil Walker Dominic Wilson	020 7533 7727
Financial Public Relations
Newgate	020 7653 9850
Tim Thompson
Robyn McConnachie Ed Treadwell

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay. 

During 2013, the Company launched the CardioQ-ODM+ monitor that offers clinicians both of the two best-established technologies, Deltex Medical's ODM technology as well as Pulse Pressure Waveform Analysis ('PPWA') in one monitor. This allows clinicians to have unique real time insights into each of flow, pressure and resistance, the three pillars of haemodynamics.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and over 600,000 patients have been treated to date using Deltex Medical's single patient disposable probes."

 

END

 

 

BOAFTMLTMBATBBA